S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.92 (+1.35%)
MSFT   370.99 (+0.59%)
META   328.02 (+3.33%)
GOOGL   138.32 (+6.38%)
AMZN   147.07 (+1.76%)
TSLA   241.75 (+0.99%)
NVDA   463.65 (+1.89%)
NIO   7.43 (-4.13%)
BABA   72.16 (+0.94%)
AMD   126.21 (+8.04%)
T   17.09 (+0.89%)
F   10.81 (+1.12%)
MU   73.67 (+0.74%)
CGC   0.73 (+3.96%)
GE   118.28 (-1.28%)
DIS   93.03 (+1.67%)
AMC   6.84 (+0.74%)
PFE   28.76 (-0.10%)
PYPL   58.35 (-1.98%)
XOM   98.45 (-0.67%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.92 (+1.35%)
MSFT   370.99 (+0.59%)
META   328.02 (+3.33%)
GOOGL   138.32 (+6.38%)
AMZN   147.07 (+1.76%)
TSLA   241.75 (+0.99%)
NVDA   463.65 (+1.89%)
NIO   7.43 (-4.13%)
BABA   72.16 (+0.94%)
AMD   126.21 (+8.04%)
T   17.09 (+0.89%)
F   10.81 (+1.12%)
MU   73.67 (+0.74%)
CGC   0.73 (+3.96%)
GE   118.28 (-1.28%)
DIS   93.03 (+1.67%)
AMC   6.84 (+0.74%)
PFE   28.76 (-0.10%)
PYPL   58.35 (-1.98%)
XOM   98.45 (-0.67%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.92 (+1.35%)
MSFT   370.99 (+0.59%)
META   328.02 (+3.33%)
GOOGL   138.32 (+6.38%)
AMZN   147.07 (+1.76%)
TSLA   241.75 (+0.99%)
NVDA   463.65 (+1.89%)
NIO   7.43 (-4.13%)
BABA   72.16 (+0.94%)
AMD   126.21 (+8.04%)
T   17.09 (+0.89%)
F   10.81 (+1.12%)
MU   73.67 (+0.74%)
CGC   0.73 (+3.96%)
GE   118.28 (-1.28%)
DIS   93.03 (+1.67%)
AMC   6.84 (+0.74%)
PFE   28.76 (-0.10%)
PYPL   58.35 (-1.98%)
XOM   98.45 (-0.67%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.92 (+1.35%)
MSFT   370.99 (+0.59%)
META   328.02 (+3.33%)
GOOGL   138.32 (+6.38%)
AMZN   147.07 (+1.76%)
TSLA   241.75 (+0.99%)
NVDA   463.65 (+1.89%)
NIO   7.43 (-4.13%)
BABA   72.16 (+0.94%)
AMD   126.21 (+8.04%)
T   17.09 (+0.89%)
F   10.81 (+1.12%)
MU   73.67 (+0.74%)
CGC   0.73 (+3.96%)
GE   118.28 (-1.28%)
DIS   93.03 (+1.67%)
AMC   6.84 (+0.74%)
PFE   28.76 (-0.10%)
PYPL   58.35 (-1.98%)
XOM   98.45 (-0.67%)

GSK Share Price, News & Analysis (LON:GSK)

GBX 1,430.50
-9.50 (-0.66%)
(As of 05:11 PM ET)
Compare
Today's Range
1,426.80
1,445.80
50-Day Range
1,382
1,521.40
52-Week Range
1,302.60
1,563.20
Volume
4.36 million shs
Average Volume
6.78 million shs
Market Capitalization
£58.65 billion
P/E Ratio
966.55
Dividend Yield
3.91%
Price Target
GBX 1,566.36

GSK MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
9.5% Upside
GBX 1,566.36 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.41mentions of GSK in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
£832,857 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars


GSK stock logo

About GSK Stock (LON:GSK)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

GSK Stock Price History

GSK Stock News Headlines

GSK is a workplace where people can thrive
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Citigroup Reiterates Neutral Rating for GSK (LON:GSK)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
GSK (LON:GSK) Receives Buy Rating from Berenberg Bank
GSK outpaces Pfizer in RSV vaccine market
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/29/2020
Ex-Dividend for 10/12 Dividend
8/17/2023
Dividend Payable
10/12/2023
Ex-Dividend for 1/11 Dividend
11/16/2023
Today
12/07/2023
Dividend Payable
1/11/2024

Industry, Sector and Symbol

Industry
Drug Manufacturers - General
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
69,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,566.36
High Stock Price Target
GBX 2,000
Low Stock Price Target
GBX 1,245
Potential Upside/Downside
+8.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
£6.08 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£29.65 billion
Cash Flow
GBX 176.79 per share
Book Value
GBX 324 per share

Miscellaneous

Outstanding Shares
4,100,000,000
Free Float
N/A
Market Cap
£59.04 billion
Optionable
Not Optionable
Beta
0.29
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 53)
    CEO & Director
    Comp: $4.79M
  • Ms. Julie Belita Brown (Age 61)
    CFO & Executive Director
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Senior VP & Group General Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Senior Vice President of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 57)
    CA, President of Corporate Development
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    President of Global Affairs

Should I Buy GSK Stock? GSK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Monday, November 27, 2023 at 10:16 AM.

Pros

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines and specialty medicines to prevent and treat various diseases. This positions the company in a crucial and high-demand sector, offering potential for long-term growth.
  • GSK plc has a strong track record of innovation and a robust pipeline of new products. This indicates the potential for future revenue growth and expansion into new markets.
  • The company has a global presence and operates in multiple countries. This diversification helps mitigate risks associated with regional economic fluctuations and regulatory changes.
  • GSK plc has a history of paying dividends to its shareholders. This can provide a steady income stream for investors, especially those seeking income-oriented investments.
  • Recent developments and advancements in GSK plc's research and development efforts have shown promising results, indicating the potential for breakthrough treatments and therapies in the future.

Cons

Investors should be bearish about investing in GSK plc for these reasons:

  • GSK plc faces intense competition in the pharmaceutical industry. This competition can impact market share and pricing power, potentially affecting the company's profitability.
  • The company's financial performance may be influenced by factors such as changes in healthcare policies, regulatory approvals, and patent expirations. These external factors can introduce uncertainties and impact the company's revenue and profitability.
  • GSK plc has experienced challenges in the past related to legal and regulatory issues. These issues can result in reputational damage and financial penalties, which may negatively impact the company's stock performance.
  • The stock price of GSK plc is subject to market volatility and fluctuations. Investors should carefully consider their risk tolerance and investment horizon before investing in the company.
  • Investing in the pharmaceutical industry carries inherent risks, including the potential for clinical trial failures, regulatory hurdles, and market uncertainties. Investors should conduct thorough research and analysis before making investment decisions.














GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price target for 2024?

8 analysts have issued 12-month price targets for GSK's shares. Their GSK share price targets range from GBX 1,245 to GBX 2,000. On average, they expect the company's share price to reach GBX 1,566.36 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2023?

GSK's stock was trading at GBX 1,437.60 on January 1st, 2023. Since then, GSK shares have decreased by 0.5% and is now trading at GBX 1,430.60.
View the best growth stocks for 2023 here
.

How were GSK's earnings last quarter?

GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 61.26% and a net margin of 20.48%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a dividend on Wednesday, November 1st. Stockholders of record on Thursday, November 16th will be given a dividend of GBX 14 per share on Thursday, January 11th. This represents a dividend yield of 0.96%. The ex-dividend date is Thursday, November 16th. The official announcement can be viewed at this link.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 56 per share and currently has a dividend yield of 4.00%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,783.78%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GSK) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -